FDA might withhold review of Biodel's VIAject insulin

08/24/2010 | Reuters

Review of Biodel's new-drug application for diabetes treatment VIAject might be withheld after the FDA warned of possible violations at a Burlington, Vt., plant that makes the vials of insulin. The agency issued the warning letter to Albany Molecular Research, which operates the manufacturing site.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI